SOURCE: Plandai Biotechnology, Inc.

Plandai Biotechnology, Inc.

May 01, 2013 08:30 ET

Stock House Group Report Initiates Coverage on Plandai Biotechnology, Inc.

NEW YORK, NY--(Marketwired - May 1, 2013) - After careful analysis, Stock House Group, a full service research and content development investor relations firm, has initiated coverage and placed a Speculative Buy Rating on Plandaí Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for the health, wellness, nutraceutical and pharmaceutical industries. A full Report accompanies the Rating placed on Plandaí Biotechnology. 

Read the Report at www.stockhousegroup.com/reports.

Stock House Group heavily weighed the company's patented technology, its highly bioavailable Phytofare™ branded products, the biotech's integrated business model, and the strong leadership team that's driving Plandaí and has written a comprehensive report to support the Rating.

Plandaí Biotechnology, Inc. believes that its technology is the foundation for creating an entirely new family of drugs that can treat a multitude of diseases and conditions safely and affordably using naturally-derived extracts.

In published USDA studies, Plandaí's proprietary plant extracts, including Phytofare™ Catechin Extract, Phytofare™ Glucoside Complex and Phytofare™ Carotenoid Extract, have shown to have improved bioavailability -- the degree to which a substance becomes available to the target tissue after administration -- of between 60-80%, far exceeding anything available today.

Read the Plandaí Biotechnology Report at www.stockhousegroup.com/reports

About Stock House Group

Stock House Group is a full service Investment Relations firm specializing in Awareness, Research, and Content Development. The firm offers a platform that allows CEOs to tell their story through the press with Feature Articles, Research Reports, and CEO Interviews. At the same time, Stock House Group is building a library of Research for Investors to use that allows them to get more informed on small cap stocks.

About Plandaí Biotechnology, Inc.

Plandaí Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its patented Phytofare™ extracts in-house, allowing the company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.

Contact Information